摘要
破伤风在现今医疗条件下的死亡率仍高达10%。长期以来,破伤风防治主要依赖破伤风抗毒素(TAT),后者主要含有马破伤风免疫球蛋白F(ab′)2和特异性抗体免疫球蛋白G(IgG)。经过多年的工艺改进,新制品马破伤风免疫球蛋白F(ab′)2因提高了可中和破伤风毒素的有效成分F(ab′)2的含量,同时降低了会引起过敏反应的主要成分IgG的含量、使不良反应发生率降低,具有良好的临床应用前景,是TAT的升级换代制品。
Despite the high-quality therapy and nursing care nowadays, mortality caused by tetanus still reaches 10 percent. Tetanus antitoxin has been used in the clinic for many years, the pharmaceutical preparation of which contains equine antitetanus immunoglobulin F（ab＇）z and immunoglobulin G. With the improvement of the preparation techonology, a new preparation ＂equine antitetanus immunoglobulin F（ab＇）2＂ comes to the stage. Equine antitetanus immunoglobulin F（ab＇）2 has a higher content of F（ab＇）2 and a lower content of immunoglobulin G which causes allergy. With its distinct qualities and promising clinical prospect, equine antitetanus immunoglobulin F（ab＇）2 can replace tetanus antitoxin in clinical applications.
出处
《上海医药》
CAS
2012年第19期13-15,共3页
Shanghai Medical & Pharmaceutical Journal
